

SAFETY DATA SHEET

PRODUCT ID: MEPIVACAINE HYDROCHLORIDE INJECTION

SECTION 15: REGULATORY INFORMATION

This product has been classified in accordance with the hazard criteria of the *Controlled Products Regulations* and the MSDS contains all the information required by the *Controlled Products Regulations*.

OSHA Regulatory Status:	Not available
-------------------------	---------------

Regulatory Status:	This product is exempt from WHMIS as a drug product
--------------------	---

SECTION 16: OTHER INFORMATION

Name of person or group that prepared MSDS:	Novocol Pharmaceutical in conjunction with a third party consultant
---	---

Phone #:	519-623-4800
----------	--------------

MSDS Version#:	# 4 (replaces V.3 of August 15, 2010)
----------------	---------------------------------------

Information and statements contained in this document have been obtained from manufacturers, suppliers and recognized reference sources as provided to or obtained by Novocol Pharmaceutical of Canada, Inc.

Novocol Pharmaceutical of Canada, Inc. believes the information to be reliable but expressly disclaims any liability for providing such information and toxicology to our customers.

SAFETY DATA SHEET

PRODUCT ID: MEPIVACAINE HYDROCHLORIDE INJECTION

	Occupational Safety and Health Administration (OSHA).
Reproductive Toxicity:	Evidence of human teratogenicity has been identified for this compound. Behavioral abnormalities have been reported in rats injected with mepivacaine.
Specific Target Organ Toxicity – Single Exposure:	Not available
Specific Target Organ Toxicity – Repeated Exposure:	May cause hypersensitivity. Associated with the development of methemoglobinemia.
Aspiration Hazard:	Not available. Not expected to be of concern.

SECTION 12: ECOLOGICAL INFORMATION

Ecotoxicity:	Not available
Persistence / Degradability:	Not available
Bioaccumulation / Accumulation:	Not available
Mobility in Environmental Media:	Not available
Other Adverse Effects:	Not available

SECTION 13: DISPOSAL CONSIDERATIONS

Disposal:	Observe all Federal/Provincial/State and Local disposal regulations.
-----------	--

SECTION 14: TRANSPORTATION INFORMATION

Basic Shipping Description:	Not available
Additional Information:	Not available
Special Precautions:	Avoid temperature extremes. Prevent from freezing.
UN Number:	Not available
UN Proper Shipping Name:	Not available
Transport Hazard Classes:	Not available
Packing Group:	Not available
Environmental Hazards:	Not available
Special Precautions for User:	Avoid temperature extremes. Prevent from freezing.

SAFETY DATA SHEET

PRODUCT ID: MEPIVACAINE HYDROCHLORIDE INJECTION

Solubility in Water	Soluble
Co-efficient of Water/Oil Distribution:	Not available
Vapour Pressure:	17 mm Hg @ 20°C
Boiling Point (°C):	100°C
Melting/Freezing Point (°C):	0°C
pH:	Not available
Vapour Density (Air=1):	0.6
Evaporation Rate (Butyl Acetate=1):	1
Flashpoint (°C) and Method:	Not flammable (water based)
Upper Flammable Limit (%):	Not available
Lower Flammable Limit (%):	Not available
Auto-ignition Temperature (°C):	Not available
Decomposition Temperature (°C):	Not available

SECTION 10: STABILITY AND REACTIVITY

Stability:	Stable
Incompatible Materials:	Incompatible with compounds which react violently with water
Conditions of Reactivity:	None
Hazardous Decomposition Products:	None

SECTION 11: TOXICOLOGICAL INFORMATION

Route of Entry:	<input checked="" type="checkbox"/> Skin Contact <input checked="" type="checkbox"/> Skin Absorption <input checked="" type="checkbox"/> Eye Contact <input checked="" type="checkbox"/> Inhalation <input checked="" type="checkbox"/> Ingestion
Acute Toxicity:	Not expected to be acutely toxic. Acute measures of toxicity (i.e. LD50 and LC50) are not available for this mixture. LD50 for Mepivacaine Hydrochloride: 310 mg/kg oral mouse
Skin Corrosion/Irritation:	May be irritating to the skin.
Serious Eye Damage/Irritation:	May be irritating to the eyes.
Respiratory or Skin Sensitization:	Not available
Interactive Effects:	Not available
Mutagenicity:	Not available
Carcinogenicity:	This product has not been listed as a carcinogen or a potential carcinogen by the ACGIH, the International Agency for Research on Cancer (IARC), the US National Toxicology Program (NTP) or the US

SAFETY DATA SHEET

PRODUCT ID: MEPIVACAINE HYDROCHLORIDE INJECTION

remove residual contamination.

SECTION 7: HANDLING AND STORAGE

Handling Procedures and Equipment:	Caution should be used to prevent against ingestion and contact with eyes. Handle with care to avoid breakage.
Storage Requirements:	Store in a cool, dry place. Avoid extremes in temperature.
Packaging:	USP Type 1 glass with rubber stopper and cap
Sensitivity to Mechanical Impact:	No
Sensitivity to Static Discharge:	No

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Limits:	Chemical Agent	Occupational Exposure Limits (OEL)			
		ACGIH ^a		Ontario	
		TWA ^b	STEL ^c	TWA ^b	STEL ^c
	Mepivacaine Hydrochloride	Not available	Not available	Not available	Not available
a – American Conference of Governmental Industrial Hygienists b – Time Weighted Average c - Short-term Exposure Limit					
Personal Protective Equipment (PPE):					
Gloves (specify):	Not normally required				
Respiratory (specify):	Not normally required				
Eye (specify):	Not normally required				
Footwear (specify):	Not normally required				
Other Equipment (specify):	RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE AVAILABLE DURING DENTAL PROCEDURES				
Engineering Controls (e.g. ventilation, enclosed process, specify):	Not normally required				

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid
Odour and Appearance:	Clear and odourless
Odour Threshold:	Not applicable
Specific Gravity (water=1):	1

SAFETY DATA SHEET

PRODUCT ID: MEPIVACAINE HYDROCHLORIDE INJECTION

	P405 – Store locked up Disposal P501 – Dispose of contents/container in accordance with local/provincial/federal regulations
WHMIS Regulatory Status:	Not WHMIS-Controlled

SECTION 3: COMPOSITION / INFORMATION ON INGREDIENTS

Chemical Identity	Concentration (Percent weight/weight)	CAS Number
Mepivacaine Hydrochloride	3	1722-62-9

SECTION 4: FIRST AID MEASURES

Inhalation:	Remove patient from exposure.
Eye Contact:	Flush eyes with plenty of water for at least 15 minutes while holding eyelids open. Get medical attention, if irritation persists.
Skin Contact:	Remove contaminated clothing. Wash skin with soap and water
Ingestion:	Get immediate medical attention. Do not induce vomiting unless instructed to do so by poison control or physician.
Injection:	Get immediate medical attention.
Personal Protective Equipment for First Aid Responders:	Wear impermeable gloves to avoid skin contact (e.g. nitrile, natural rubber).

SECTION 5: FIRE FIGHTING MEASURES

Suitable extinguishing media:	Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials
Hazardous Combustion Products:	Not available
Special Protective Actions for Firefighters:	As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal precautions:	Caution should be used to prevent against ingestion and contact with eyes. Wear safety glasses with side shields.
Environmental precautions:	Prevent spills from entering sewers and watercourses. Cover drains.
Methods and materials for containment and cleaning up:	Clean up spills with normal procedures used for non-hazardous liquids. This can include: absorb spill with inert material, then place in a chemical waste container. Clean surface thoroughly with water to


SAFETY DATA SHEET

PRODUCT ID: MEPIVACAINE HYDROCHLORIDE INJECTION

SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

Product Name:	Mepivacaine Hydrochloride 3% Injection
Brand Name:	3% POLOCAINE® DENTAL (Mepivacaine Hydrochloride 3%, Injection)
Manufacturer / Supplier:	DENTSPLY Pharmaceutical 1301 Smile Way York, PA, USA 1-800-989-8825 http://www.dentsply.com
Prepared By:	Novocol Pharmaceutical in conjunction with a third party consultant
Emergency Phone Number:	1-416-522-3854
Product Use:	Local anesthetic solution for use in peripheral nerve blocks
Date of Preparation:	July 19, 2013

SECTION 2: HAZARDS IDENTIFICATION

Classification:	Narcotic effects, Category 3
GHS Label Symbol:	
Hazard Statements:	<p>Warning</p> <p>H336 - May cause drowsiness or dizziness</p> <p>May cause skin and/or eye irritation</p> <p>Causes central nervous system effects such as drowsiness, confusion, excitability and nervousness. Acts as a depressant on the cardiovascular system.</p> <p>Avoid use in individuals with hypersensitivities to amide-type anesthetics. Use with caution in individuals with diabetes and/or severe hypertension.</p> <p>CONSULT PRODUCT INSERT FOR CLINICAL AND PHARMACOLOGICAL INFORMATION</p> <p>Signs and Symptoms of Overexposure: Drowsiness, confusion, excitability, nervousness, drop in blood pressure, fatigue, bluish discoloration of fingernails, lips, or skin, difficulties in breathing.</p> <p>DOES NOT CONTAIN SODIUM BISULFITE</p>
Precautionary Statements:	<p>Prevention</p> <p>P261 – Do not breathe mist/vapours/spray</p> <p>P271 – Use in a well-ventilated area</p> <p>Response</p> <p>P304+P430 – If inhaled – remove victim to fresh air and keep at rest in a position comfortable for breathing</p> <p>P312 – Call a POISON CENTER or doctor/physician if you feel unwell</p> <p>Storage</p>